Biomarker study for newly diagnosed thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at blood and urine samples from people newly diagnosed with papillary thyroid cancer or suspected follicular thyroid tumors. The goal is to find biomarkers that help predict risk and monitor the disease after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been newly diagnosed with papillary thyroid cancer (a common type of thyroid cancer) or have a suspicious follicular thyroid tumor (including those that might turn into a more aggressive cancer).
- You have not yet started treatment for this condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a small blood test (called ctDNA) and tumor tissue to understand how advanced thyroid cancers change over time. It may help doctors better monitor cancer growth and guide treatment choices.
This study looks at the genes and mutations in thyroid cancers that start in follicular cells. It aims to understand how these changes relate to how aggressive the cancer is.
This study is a registry that collects information about adults with certain types of thyroid cancer. It may help researchers learn more about these cancers and how people are doing over time.
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
This study tests if an online educational program helps people newly diagnosed with small thyroid nodules better understand their condition and treatment options before visiting the clinic. It aims to reduce anxiety and prepare you for discussions with your doctor.
This study is looking at how certain substances in the blood (called biomarkers) can help doctors understand and treat advanced thyroid cancer. It is for people who are about to start their first systemic therapy (medication that works throughout the body) for advanced thyroid cancer, and who have already had a genetic test on their tumor.
Hear when a new Genomics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.